Combination of radiotherapeutics and mTOR inhibitors preclinically tested for [177Lu]Lu-PP-F11N in mice, has resulted in improvement of tumor uptake, presumably via the CCK2R-upregulation in tumor cells, offering hopes for a successful translation in the clinic [160]. Here, MTOR is linked to neoplasm.